摘要
目的 观察罗沙司他和促红细胞生成素(EPO)治疗肾性贫血的临床效果。方法 选取2020年8月至2022年7月濮阳市安阳地区医院收治的56例肾性贫血患者,按照随机数字表法分为对照组和研究组,各28例。对照组接受EPO治疗,研究组接受罗沙司他治疗。比较两组疗效、治疗前后血清炎症因子[白细胞介素-6(IL-6)、C反应蛋白(CRP)]水平、贫血指标[血红蛋白(Hb)、血细胞比容(Hct)、红细胞计数(RBC)]、铁代谢指标[血清铁蛋白(SF)、总铁结合力(TIBC)、转铁蛋白饱和度(TSAT)]及不良反应发生情况。结果 研究组治疗总有效率高于对照组(P<0.05)。治疗前两组IL-6、CRP水平比较,差异无统计学意义(P>0.05);治疗后研究组IL-6、CRP水平低于对照组(P<0.05)。治疗前两组Hb、Hct、RBC水平比较,差异无统计学意义(P>0.05);治疗后研究组Hb、Hct、RBC水平高于对照组(P<0.05)。治疗前两组SF、TIBC、TSAT水平比较,差异无统计学意义(P>0.05);治疗后研究组SF、TIBC、TSAT水平高于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论 与EPO相比,罗沙司他治疗肾性贫血效果较好,可减轻机体炎症,改善贫血指标和铁代谢指标,且治疗安全性良好。
Objective To observe the clinical effect of roxadustat and erythropoietin(EPO)in the treatment of renal anemia.Methods A total of 56 patients with renal anemia admitted to Anyang District Hospital of Puyang from August 2020 to July 2022 were randomly divided into a control group and a study group,with 28 patients in each group.The control group received EPO treatment,and the study group received rosalitam treatment.The efficacy and levels of serum inflammatory factors[interleukin-6(IL-6),C-reactive protein(CRP)],anemia indicators[hemoglobin(Hb),hematocrit(Hct),red blood cell count(RBC)],iron metabolism indicators[serum ferritin(SF),total iron binding capacity(TIBC),transferrin saturation(TSAT)]before and after treatment and occurrence of adverse reactions were compared.Results The total effective rate of treatment in the study group was higher than that in the control group(P<0.05).Before treatment,there were no statistically differences in the levels of IL-6 and CRP between the two groups(P>0.05).After treatment,the levels of IL-6 and CRP in the study group were lower than those in the control group(P<0.05).There were no statistically differences in Hb,Hct,and RBC levels between the two groups before treatment(P>0.05).After treatment,the levels of Hb,Hct,and RBC in the study group were higher than those in the control group(P<0.05).Before treatment,there were no statistically differences in the levels of SF,TIBC,and TSAT between the two groups(P>0.05).After treatment,the levels of SF,TIBC,and TSAT in the study group were higher than those in the control group(P<0.05).There was no statistically difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Compared with EPO,roxadustat can improve the efficacy,reduce inflammation,improve anemia indexes and iron metabolism indexes in the treatment of renal anemia,with good safety.
作者
王慧娟
桑瑜
WANG Huijuan;SANG Yu(Department of Nephropathy and Rheumatology,Anyang District Hospital of Puyang,Anyang 455000,China)
出处
《河南医学研究》
CAS
2023年第8期1478-1481,共4页
Henan Medical Research
